NCT06425926 - Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

November 30, 2026

Conditions

Melanoma Stage IVSolid Tumor

Interventions

DRUG

GIM-531

GIM-531 administered orally daily

DRUG

Anti-PD-1 monoclonal antibody

Continued treatment with anti-PD-1 therapy

Trial Locations (11)

10065

RECRUITING

Weill Cornell Medicine - New York Presbyterian Hospital, New York

23219

RECRUITING

Virginia Commonwealth University, Richmond

37203

RECRUITING

Tennessee Oncology, PLLC, Nashville

45267

RECRUITING

University of Cincinnati Cancer Center, Cincinnati

59102

RECRUITING

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings

85258

RECRUITING

HonorHealth Research Institute, Scottsdale

90025

RECRUITING

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles

92835

RECRUITING

Providence Medical Foundation, Fullerton

93309

RECRUITING

Comprehensive Blood and Cancer Center, Bakersfield

94143

RECRUITING

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

02114

RECRUITING

Massachusetts General Hospital, Boston